Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six
Novo Nordisk released full Phase 3 trial results showing Wegovy lowered BMI and obesity rates in children aged 6 and older, though younger children who took the drug showed reduced growth rates.
·3 sources